T-cell immunotherapy: looking forward

Affiliations

¹ Office of Science Policy, Office of the Director, National Institutes of Health, Bethesda, Maryland, USA.
² Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
³ California Institute of Technology, Pasadena, California, USA.
⁴ Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
⁵ MD Anderson Cancer Center, Houston, Texas, USA.
⁶ City of Hope, Duarte, California, USA.
⁷ Baylor College of Medicine, Houston, Texas, USA.
⁸ Roger Williams Medical Center, Providence, Rhode Island, USA.
⁹ University of Washington, Seattle, Washington, USA.
¹⁰ National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
¹¹ Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹² David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Jacqueline Corrigan-Curay et al. Mol Ther. 2014 Sep.

. 2014 Sep;22(9):1564-74.

doi: 10.1038/mt.2014.148.

¹ Office of Science Policy, Office of the Director, National Institutes of Health, Bethesda, Maryland, USA.
² Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
³ California Institute of Technology, Pasadena, California, USA.
⁴ Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
⁵ MD Anderson Cancer Center, Houston, Texas, USA.
⁶ City of Hope, Duarte, California, USA.
⁷ Baylor College of Medicine, Houston, Texas, USA.
⁸ Roger Williams Medical Center, Providence, Rhode Island, USA.
⁹ University of Washington, Seattle, Washington, USA.
¹⁰ National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
¹¹ Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹² David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

No abstract available

Figures

1. Eshhar Z, Waks T, Gross G., and, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90:720–724. - PMC - PubMed
1. Sadelain M, Brentjens R., and, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–398. - PMC - PubMed
1. Ertl HC, Zaia J, Rosenberg S, June C, Dotti G, Kahn J.et al. (2011Considerations for the clinical application of chimeric antigen receptor T cells: observations from a Recombinant DNA Advisory Committee Symposium held June 15, 2010 Cancer Res 713175–3181. - PMC - PubMed
1. Brentjens R, Davila M, Riviere I, Park J, Wang X, Cowell L.et al. (2013CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Sci Transl Med 5177ra38 - PMC - PubMed
1. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold R.et al. (2013Chimeric antigen receptor–modified T cells for acute lymphoid leukemia N Engl J Med 3681509–1518. - PMC - PubMed